Satish Mata
Managing Director and CEO
Notable Quotes
We crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.
Our adjusted PAT grew more than 40%, I repeat, our adjusted PAT grew more than 40%.
FY27 we project low to mid-teen revenue growth and as I have been explaining... margin expansion will happen as committed between 75 to 100 basis points going forward assuming stable regulations and macroeconomic conditions.
We became the only company to launch the innovator drug in the game changing semaglutide category.
We don't have any significant presence in US, so we don't worry about on which side of the bed Mr. Trump gets up.